The Effects of Probiotics on Depression: Can a Daily Drink of Good Bacteria Improve Mental Wellbeing?

Not Applicable

Completed

• Conditions: Depression; Mental Health - Depression

• Registration Number: ACTRN12615001081505
• Lead Sponsor: niversity of Technology Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Participants must be aged 18 years or above, and at screening have a subclinical or clinical diagnosis of Major Depressive Disorder confirmed using the Mini International Neuropsychiatric Interview (M.I.N.I). Participants must be able to travel to UTS (Ultimo) to participate in the study, and must have access to and regularly check a valid email address. Participants must also be willing to complete questionnaires measuring mood, general wellbeing and health, as well as a measure of blood pressure and a stool sample

Exclusion Criteria

Key exclusion criteria: Participants will be excluded from the trial if they meet any of the following restrictions: currently taking antibiotics or probiotic supplements, taken antibiotics within the 2 weeks prior to the start of the trial, diagnosed with HIV/AIDS, cancer, Crohn’s disease or ulcerative colitis, currently undergoing chemotherapy, lactose-intolerant, gluten-intolerant, high-risk alcohol consumption, experiencing severe depressive symptoms, actively suicidal or experiencing severe suicidal ideation, actively self-harming, pregnant or planning to be pregnant within the time-course of this study, diagnosed with Bipolar disorder, a Personality disorder, a psychotic disorder or otherwise experiencing psychosis, receiving any other treatment for mental health issues (including medications such as anti-depressants) or currently participating in another clinical trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of participants with subclinical or clinical diagnosis of Major Depressive Disorder (MDD), on the Mini International Neuropsychiatric Interview (M.I.N.I)[baseline, post-intervention (8 weeks)];mean score on the Beck Depression Inventory – II[baseline, post-intervention (8 weeks)];mean score on the Depression Anxiety Stress Scale-21[weekly, beginning at baseline through to the end of the intervention period (8 weeks)]

Secondary Outcome Measures

Name	Time	Method
mean score on Beck Anxiety Inventory [baseline, post-intervention (8 weeks)];mean score on Cognitive Reactivity Scale[baseline, post-intervention (8 weeks)]